Target type: biologicalprocess
Any process that increases the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. [GOC:BHF, GOC:dph, GOC:tb]
Positive regulation of high-density lipoprotein (HDL) particle clearance is a complex process involving multiple steps and cellular components. It is essential for maintaining cholesterol homeostasis and preventing the accumulation of harmful lipids in the bloodstream.
**Step 1: Recognition and Binding:** HDL particles, which carry cholesterol from peripheral tissues to the liver, are recognized by specific receptors on the surface of liver cells (hepatocytes). The major receptor involved is the scavenger receptor class B type I (SR-BI), which binds to HDL particles and facilitates the selective transfer of cholesterol esters from HDL to the liver cell.
**Step 2: Internalization and Degradation:** Once bound to SR-BI, HDL particles can be internalized into hepatocytes via endocytosis. However, HDL particles are not always fully internalized. Instead, they can undergo a process called "selective uptake," where cholesterol esters are transferred to the liver cell without the entire particle being taken in. This mechanism is crucial for maintaining the integrity and function of HDL particles in the circulation.
**Step 3: Cholesterol Metabolism and Excretion:** Once inside the liver cell, cholesterol esters are hydrolyzed by enzymes to release free cholesterol. This free cholesterol can then be used for various purposes, including the synthesis of bile acids, a major route for cholesterol excretion. Excess cholesterol can also be re-esterified and packaged into very low-density lipoprotein (VLDL) particles, which are secreted into the circulation.
**Factors Regulating HDL Clearance:**
- **SR-BI Expression:** The expression of SR-BI on liver cells is regulated by various factors, including hormones, dietary components, and genetic factors. Increased SR-BI expression leads to enhanced HDL clearance.
- **HDL Particle Size and Composition:** Smaller, denser HDL particles are more efficiently cleared from the circulation than larger, less dense particles. The composition of HDL particles, including the ratio of cholesterol esters to phospholipids, can also affect their clearance rate.
- **Metabolic State:** The metabolic state of the body can influence HDL clearance. For example, fasting or prolonged exercise can stimulate HDL clearance.
**Clinical Significance:**
Defects in HDL clearance can contribute to the development of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. This can lead to heart attacks and strokes. Therefore, understanding and promoting the efficient clearance of HDL particles is critical for cardiovascular health.
**Summary:**
Positive regulation of HDL particle clearance involves the recognition and binding of HDL particles by SR-BI on liver cells, followed by internalization and degradation, and finally the metabolism and excretion of cholesterol. The process is regulated by various factors, and its proper function is essential for maintaining cholesterol homeostasis and preventing cardiovascular disease.'
"
Protein | Definition | Taxonomy |
---|---|---|
Endothelial lipase | An endothelial lipase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y5X9] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
nutlin 3 | stilbenoid | ||
orlistat | orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity. | beta-lactone; carboxylic ester; formamides; L-leucine derivative | anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor |
xen445 |